Published in final edited form as:

Org Lett. 2009 September 3; 11(17): 4010–4013. doi:10.1021/ol901676f.

Catalytic Asymmetric Alkylation of Substituted Isoflavanones

Antoinette E. Nibbs, Amanda-Lauren Baize, Rachel M. Herter, and Karl A. Scheidt

Department of Chemistry, Center for Molecular Innovation and Drug Discovery, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208

Abstract

The asymmetric alkylation of isoflavanones and protected 3-phenyl-2,3-dihydroquinolin-4(1*H*)-ones catalyzed by a novel cinchonidine-derived phase transfer catalyst **E** is reported. This functionalization occurs at the non-activated C3 methine to afford novel products that can easily be functionalized to generate more complex fused ring systems. The process accommodates a variety of isoflavanones and activated electrophiles and installs a stereogenic quaternary center in high yield and with good-to-excellent selectivity.

Isoflavanones (3-aryl-chroman-4-ones) are a privileged class of natural products with a broad spectrum of biological activities including insecticidal, antimicrobial, antibacterial, estrogenic, antitumor, and anti-HIV activity.¹ Isoflavanones are also precursors for more complex natural products such as pterocarpanes and rotenones.¹ Given their therapeutic promise, selective strategies to access new classes of isoflavanones and related structures has high value.² The functionalization of the C3 position could promote beneficial interactions with biological targets of interest. Specifically, an alkylation at C3 can rapidly access new members of the general class of biologically active homoisoflavanones.³

The installation of stereodefined quaternary centers⁴ in aryl-substituted indanones has been reported⁵ but the corresponding methodology for the related isoflavanones has not been developed to the same extent. The larger core structure of isoflavanones (six carbons versus five for indanones) and potential scission of the C-O bond via elimination under basic conditions make modifications at C3 with established approaches a challenging endeavor. The palladium-catalyzed asymmetric alkylations of enol carbonates developed independently by Stoltz and Trost is restricted to allyl electrophiles and related structures by virtue of the reaction mechanism.⁶ Alkylations of aryl ketones with a strongly electron-withdrawing group (F, CO₂R, CN) in the α -position have recently been reported separately by Deng, Dixon and Jorgensen using phase transfer catalysis (PTC).⁷ Transition metal-catalyzed enantioselective α -arylations of tetralones and indanones have also been reported, but surprisingly, these reactions have focused predominately on α -methyl substituted substrates.⁸ To date, a general solution to produce C3-substituted isoflavanones efficiently with high enantiomeric excess for the newly formed quaternary stereogenic center has not emerged. We report herein the direct

asymmetric alkylation of isoflavanones (**1**, Y=O) and protected 3-phenyl-2,3-dihydroquinolinones (**1**, Y=NP) catalyzed by a new cinchonidine-derived quaternary ammonium salt to afford alkylated heterocycles (**2**, eq. 1).

Our studies began by treating isoflavanone (**1a**) with allyl bromide and surveying various cinchonidine-derived quaternary ammonium salts and reaction conditions (Table 1). Initial problems of low conversion were circumvented by using excess base and alkyl halide to consume **1a**, which allowed us to focus our attention on obtaining optimal selectivities. Employing catalyst **A** and 50% aqueous KOH as the base at ambient temperature provided encouraging results (15% ee, entry 1). Cooling the reaction to 0 °C resulted in a minor increase in enantioselectivity (21% ee, entry 2). Vigorous stirring of the reaction increased the reaction rate, as did increasing the catalyst loading from 5 mol % to 10 mol %, but neither modification dramatically improved the stereoselectivity of the reaction.

We hypothesized that a larger nitrogen substituent appended to the quinuclidine core might improve the stereoselectivity, which led us to employ well known phase-transfer catalyst **B**.⁹ This modulation and changing the base from aqueous KOH to solid CsOH·H₂O provided a moderate increase in enantiomeric excess (entry 3), which improved slightly when the reaction temperature was lowered (-40 °C, entry 4). Further cooling to -78 °C (entry 5) resulted in a longer reaction time and comparable selectivity, so we continued our optimization studies at -40 °C. While we were pleased with the slight increase in selectivity observed when employing a co-solvent (entry 6), we remained dissatisfied with the level of asymmetric induction, so we investigated other catalysts. The previously reported catalyst **C**¹⁰ with toluene as the solvent afforded **2a** with 76% ee (entry 7), and 78% ee with 9:1 PhMe/CH₂Cl₂ as the solvent (entry 8).¹¹ The success of this catalyst indicates that the bulk of the R substituent is crucial for significant asymmetric induction.

The 3,5-diphenyl benzyl-ammonium catalyst **D** afforded **2a** with the same selectivity (entry 9) as observed catalyst **B** (44% ee, entry 4). After an extensive survey, the new catalyst with the specific 2,5-biaryl substitution pattern (**E**) afforded the C3-allylated isoflavanone **2a** with 83% ee (entry 10). The optical purity could be improved to 97% ee with a single recrystallization. While the lack of covalent bonding with PTC makes providing a model for stereoinduction with **E** difficult, it is clear that the placement of phenyl rings in the 2 and 5 positions on the benzyl fragment allows for the formation of the contact ion pair necessary for high levels of stereoinduction. Single crystal x-ray diffraction analysis of salt **3**, derived from isoflavanone **2a**, allowed for the assignment of the absolute stereochemical configuration (and other products, by analogy) as the *R* enantiomer.

We next examined the scope of this reaction with regard to alkyl halides (Table 2). Alkylation of isoflavanone with a variety of alkyl halides gave products in good yields and with high to excellent enantioselectivities (entries 1-7). While alkylation with methyl, and crotyl bromide gave products with 82-86% ee (entries 1-2), alkylation with cinnamyl chloride gave a selectivity of 92% ee (entry 3). Alkylations employing substituted benzyl halides typically necessitated longer reaction times, but also generally afforded products with higher selectivities (entries 5-6) as compared to the allylation processes. The reaction with TMS-propargyl bromide provided the desired product in good yield and 76% ee (entry 7).

The reaction tolerates electron-withdrawing aromatic substitution on the pendant C3 aryl ring with moderate-to-excellent levels of enantioselectivity. Alkylation of the 2-naphthyl analog of isoflavanone (entries 8-9) gave products with selectivities comparable to those of the alkylations of isoflavanone. Substrates with C3 aryl rings possessing carbon-based *ortho* substituents resulted only *O*-alkylation, but alkylation of 2'-fluoroisoflavanone (entry 10) resulted in only *C* alkylation, albeit with 80% ee. We were pleased to find that employing 4'-

chloroisoflavanone afforded products with high levels of enantioselectivity (entries 12-13). However, electron-donating substituents on the C3 aryl ring (entry 11) consistently afforded products with lower selectivities. Electron-donating groups at the C7 position also afforded products with lower selectivities (< 60% ee, not shown), but interestingly, C7 electron-withdrawing groups (entry 14) did not dramatically increase or decrease selectivity.

In our investigations of the nucleophile scope of this reaction, we tested different benzocyclic ketones, modifying the ring size and also the substitution of **Y**. Alkylation of tetralones proved to be surprisingly difficult; the reactions rarely went to completion, even over a period of seven days, and the selectivity was surprisingly low (< 50 % ee). While the alkylations of 1-phenyl indanone resulted in complete conversion to the desired products, selectivities comparable to those of tetralones were observed. We hypothesize that the planarity of the enolate is crucial for formation of a tight, contact ion pair with the cinchonidine-derived catalyst.^{7a} This optimal planarity is achieved with the flavanones but not with tetralones or indanones.¹² To test our hypothesis, we subjected various protected 3-phenyl-2,3-dihydroquinolin-4(1*H*)-ones (**1**, **Y** = NP) to the reaction conditions above. We were pleased to find that employing the *N*-Alloc quinolone gave products between 86 and 91% ee (entries 15-17). These molecules are of particular interest to us given their limited biological and synthetic studies.¹³

With an efficient pathway to access alkylated isoflavanones and aza-isoflavanones, we have started to explore the synthetic utility of these compounds (Scheme 1). An ozonolysis/aldol condensation sequence from **2b** delivers enones such as **5** with high optical purity.¹⁴ Alternatively, the exposure of ketone **2b** to reducing conditions followed by strong acid facilitates a Prins cyclization to afford a mixture of alkenes with >20:1 *cis* relative stereochemistry at the ring fusion. A subsequent reduction (Pd/C, hydrogen) approaches from the convex face of the tricyclic system and generates cyclopentane **7** in excellent yield.

Driven by the potential utility of optically active C3-substituted isoflavanones, we have developed the first enantioselective alkylation of these heterocycles (**1**, **Y** = O) and related nitrogen analogs (**1**, **Y** = NAlloc) employing a new cinchonidine-derived phase transfer catalyst **E**. The process accommodates a variety of isoflavanones and activated electrophiles and installs a stereogenic quaternary center in high yield and with good to excellent levels of enantioselectivity. This mild alkylation adds isoflavanones to the general compound classes for successful and useful enantioselective PTC and affords products from simple starting materials that can be easily transformed into novel heterocycles. Further reaction development with this new PTC catalyst and the application of the polycyclic products are ongoing in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

Support for this work was provided by the NIH (NCI CA126827), the American Cancer Society (Research Scholar Award), the H Foundation, GlaxoSmithKline, AstraZeneca and the Sloan Foundation. A.E.N. thanks the NIH for a predoctoral fellowship (F31CA13132617) and is a 2009 Malkin Scholar. R.M.H. and A.B. thank NU for Summer Research Grants. We thank John M. Roberts (NU) for assistance with X-ray crystallography.

References

1. Harborne, J.B.; Baxter, H., editors. *The Handbook of Natural Flavonoids*. Vol. 1 and 2. Wiley; Chichester, U.K.: 1999. Andersen, O.M.; Markham, K.R., editors. *Flavonoids: Chemistry, Biochemistry and Applications*. CRC Press; Boca Raton: 2006.

2. (a) Skouta R, Li CJ. *Angew. Chem. Int. Ed* 2007;46:1117–1119. (b) Skouta R, Li CJ. *Synlett* 2007:1759–1762. (c) Rahman MM, Gibbons S, Gray AI. *Phytochemistry* 2007;68:1692–1697. [PubMed: 17540419] (d) Rukachaisirikul T, Innok P, Suksamram A. *J. Nat. Prod* 2008;71:156–158. [PubMed: 18171023]
3. (a) Heller W, Tamm C. *Fortschr. Chem. Org. Naturst* 1981;40:105–152. (b) Heller W, Tamm C. *Fortschr. Chem. Org. Naturst* 1981;40:128–145. (c) Adinolfi M, Barone G, Belardini M, Lanzetta R, Laonigro G, Parrilli M. *Phytochemistry* 1985;24:2423–2426.
4. For reviews see:(a)Corey EJ, Guzman-Perez A. *Angew. Chem. Int. Ed* 1998;37:388–401.(b) Douglas CJ, Overman LE. *Proc. Nat. Acad. Sci. U.S.A* 2004;101:5363–5367.(c)Trost BM, Jiang CH. *Synthesis* 2006:369–396.(d)Cozzi PG, Hilgraf R, Zimmermann N. *Eur. J. Org. Chem* 2007:5969–5994.5994
5. (a)Dolling UH, Davis P, Grabowski EJJ. *J. Am. Chem. Soc* 1984;106:446–447.(b)Hughes DL, Dolling UH, Ryan KM, Schoenewaldt EF, Grabowski EJJ. *J. Org. Chem* 1987;52:4745–4752.(c) Ducry L, Diederich F. *Helv. Chim. Acta* 1999;82:981–1004.(d)For recent reviews on chiral PTC, see:(d)Hashimoto T, Maruoka K. *Chem. Rev* 2007;107:5656–5682 [PubMed: 18072806](e)Ooi T, Maruoka K. *Angew. Chem. Int. Ed* 2007;46:4222–4266.4266
6. (a) Behenna DC, Stoltz BM. *J. Am. Chem. Soc* 2004;126:15044–15045. [PubMed: 15547998] (b) Trost BM, Xu JY. *J. Am. Chem. Soc* 2005;127:2846–2847. [PubMed: 15740108] (c) Mohr JT, Behenna DC, Harned AM, Stoltz BM. *Angew. Chem. Int. Ed* 2005;44:6924–6927.
7. (a) Arai S, Oku M, Ishida T, Shioiri T. *Tetrahedron Lett* 1999;40:6785–6789. (b) Wang BM, Wu FH, Wang Y, Liu XF, Deng L. *J. Am. Chem. Soc* 2007;129:768–769. [PubMed: 17243806] (c) Rigby CL, Dixon DJ. *Chem. Commun* 2008:3798–3800. (d) Moss TA, Fenwick DR, Dixon DJ. *J. Am. Chem. Soc* 2008;130:10076–10077. [PubMed: 18616245] (e) Paixao MW, Nielsen M, Jacobsen CB, Jorgensen KA. *Org. Biomol. Chem* 2008;6:3467–3470. [PubMed: 19082146]
8. (a) Ahman J, Wolfe JP, Troutman MV, Palucki M, Buchwald SL. *J. Am. Chem. Soc* 1998;120:1918–1919. (b) Hamada T, Chieffi A, Ahman J, Buchwald SL. *J. Am. Chem. Soc* 2002;124:1261–1268. [PubMed: 11841295] (c) Chen GS, Kwong FY, Chan HO, Yu WY, Chan ASC. *Chem. Commun* 2006:1413–1415. (d) Liao XB, Weng ZQ, Hartwig JF. *J. Am. Chem. Soc* 2008;130:195–200. [PubMed: 18076166]
9. (a) Corey EJ, Xu F, Noe MC. *J. Am. Chem. Soc* 1997;119:12414–12415. (b) Lygo B, Wainwright PG. *Tetrahedron Lett* 1997;38:8595–8598.
10. Park EJ, Kim MH, Kim DY. *J. Org. Chem* 2004;69:6897–6899. [PubMed: 15387619]
11. Using polar aprotic solvents as the sole solvent for the reaction (not shown) resulted in significantly lower selectivities.
12. The impact of these subtle structural changes is under investigation.
13. Daruwala AB, Gearien JE, Dunn WJ, Benoit PS, Bauer L. *J. Med. Chem* 1974;17:819–824.824 [PubMed: 4845375](b) see ref. 2b.
14. For the 2-methyltetralone analog of **5**, see:Clift MD, Taylor CN, Thomson RJ. *Org. Lett* 2007;9:4667–4669.4669 [PubMed: 17914838]

Figure 1.
Phase transfer alkylation of unactivated benzocyclic ketones (this work)

Figure 2.
ORTEP of Isoflavanone **3**

Scheme 1.
Functionalization of Isoflavanone **2b**

Table 1

Optimization of Allylation Conditions

 10 mol % catalyst conditions					
entry	catalyst	solvent	base	temp (°C)	ee (%) ^b
1	A	PhMe	50% aq KOH	23	15
2	A	PhMe	50% aq KOH	0	21
3	B	PhMe	CsOH·H ₂ O	0	30
4	B	PhMe	CsOH·H ₂ O	-40	44
5	B	PhMe	CsOH·H ₂ O	-78	43
6	B	7:3 PhMe/CH ₂ Cl ₂	CsOH·H ₂ O	-40	49
7	C	PhMe	CsOH·H ₂ O	-40	76
8	C	9:1 PhMe/CH ₂ Cl ₂	CsOH·H ₂ O	-40	78
9	D	9:1 PhMe/CH ₂ Cl ₂	CsOH·H ₂ O	-40	44
10	E	9:1 PhMe/CH ₂ Cl ₂	CsOH·H ₂ O	-40	83 (97%) ^b

entry	catalyst	solvent	base	temp (°C)	ee (%) ^b

^aDetermined by HPLC Chiralcel OD-H.^b% ee after recrystallization.

Table 2

Reaction Scope^a

entry	ketone	R ² X	pdt	ee (%) ^b	yield (%) ^c
1		methallyl bromide	2b	86	70
2		crotyl bromide	2c	82	70

entry	ketone	R^2X	pdt	ee (%) ^b	yield (%) ^c
3		cinnamyl chloride	2d	92	62
4		benzyl bromide	2e	86	69
5		4-Br- $\text{C}_6\text{H}_4\text{CH}_2\text{Br}$	2f	87	67
6		4-F- $\text{C}_6\text{H}_4\text{Cl}$	2g	91	69
7		$\text{BrH}_2\text{C}\equiv\text{TMS}$	2h	76	85

entry	ketone	R ² X	pdt	ee (%) ^b	yield (%) ^c
8		methallyl bromide	2j	81	99
9		benzyl bromide	2k	87	76
10		benzyl bromide	2l	80	96

entry	ketone	R ² X	pdt	ee (%) ^b	yield (%) ^c
11		benzyl bromide	2m	77	66
12		methallyl bromide	2n	90	76
13		benzyl bromide	2o	90	82

entry	ketone	R^2X	pdt	ee (%) ^b	yield (%) ^c
14		benzyl bromide	2p	85	69

entry	ketone	R^2X	pdt	ee (%) ^b	yield (%) ^c
15		allyl bromide	2q	89	70
16		cinnamyl bromide	2r	91	84
17		4-Br- $\text{C}_6\text{H}_4\text{CH}_2\text{Br}$	2s	86	76

entry	ketone	R ² X	pdt	ee (%) ^b	yield (%) ^c
Org Lett. Aut					

General conditions: ketone **1** (1 equiv), R^2X (1.5 equiv), catalyst **E**, $C_6H_5OH:H_2O$, 9:1 $PhMe/CH_2Cl_2$ (0.1 M), $-40^\circ C$.

Enantiomeric excess determined by HPLC Chiralcel O-DH, AD-H, or Whelk-O-I.

Isolated yields.